Company Profile
Annexon, Inc. Stock Price, News & Analysis
- Ticker:
- ANNX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
5.60 USD (+4.28%)
Close
Last updated: August 6, 2026
862M USD
Market cap
Why the stock is moving
Following the latest company update, “Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week”, ANNX closed up 4.28% at $5.60 on Aug 6, 2026. The move occurred in the trading session associated with this clinical readout update.
Company overview
Classical Complement Inhibition
Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic and autoimmune diseases.
Vonaprument
Vonaprument is a complement inhibitor in pivotal development for geographic atrophy, an advanced form of dry age-related macular degeneration. The program aims to preserve vision by blocking upstream complement activation.
Tanruprubart
Tanruprubart is an antibody therapy under regulatory review in Europe and preparing for a U.S. submission in Guillain-Barré syndrome.
ANX1502
ANX1502 is an oral C1 inhibitor intended to extend classical-complement modulation into chronic autoimmune diseases that may require convenient long-term treatment.
Future catalysts
BLA submission for tanruprubart in Guillain-Barré syndrome during 2026.
Proof-of-concept data for ANX1502 during 2026.
Topline pivotal Phase 3 data for vonaprument in the fourth quarter of 2026.
Recent news
- 01
- 02
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Source: Annexon, Inc.
- 03
- 04
- 05
Annexon to Participate in Upcoming June Investor Conferences
Source: Annexon, Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Annexon, Inc. (ANNX)?
Annexon, Inc. (ANNX) most recently closed at 5.60 USD, a +4.28% move versus the previous session.
What is the market cap of Annexon, Inc. (ANNX)?
Annexon, Inc. currently has a market capitalization of 862M USD on BioPharmSignal.
What does Annexon, Inc. do?
Classical Complement Inhibition Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic and autoimmune diseases. Vonaprument Vonaprument is a complement inhibitor in pivotal development for geographic atrophy, an advanced form of dry age-related macular...
On which exchange is ANNX stock listed?
Annexon, Inc. (ANNX) is associated with NASDAQ, United States, Biopharma.
What is of-concept?
Proof-of-concept data for ANX1502 during 2026.
Which conditions is Annexon, Inc. targeting with of-concept?
Annexon, Inc. is associated with inflammatory disease based on its company overview and current catalyst commentary.
How does Annexon, Inc. describe recent progress with of-concept?
Proof-of-concept data for ANX1502 during 2026.
What is Classical?
Classical Complement Inhibition Annexon develops therapies that inhibit the classical complement pathway, which can drive harmful inflammation and tissue damage in neurologic, ophthalmic and autoimmune diseases.